Influence of genetic co-mutation on chemotherapeutic outcome in NPM1-mutated and FLT3-ITD wild-type AML patients.

ABSTRACT:

Background

Nucleophosmin 1 (NPM1) gene-mutated acute myeloid leukemia (NPM1^mut AML) is classified as a subtype with a favorable prognosis. However, some patients fail to achieve a complete remission or relapse after intensified chemotherapy. Genetic abnormalities in concomitant mutations contribute to heterogeneous prognosis of NPM1^mut AML patients.

Methods

In this study, 91 NPM1-mutated and FLT3-ITD wild-type (NPM1^mut/FLT3-ITD^wt) AML patients with intermediate-risk karyotype were enrolled to analyze the impact of common genetic co-mutations on chemotherapeutic outcome.

Results

Our data revealed that TET1/2 (52/91, 57.1%) was the most prevalent co-mutation in NPM1^mut AML patients, followed by IDH1/2 (36/91, 39.6%)

SUBMITTER: Wu Q 

PROVIDER: S-EPMC11316012 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature